Sponsored Links
| Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis |
 |
 |
 |
| Medical News - Cystic Fibrosis | |||
|
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE)... Read more: Cystic Fibrosis News From Medical News Today
|